Status:
UNKNOWN
The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants
Lead Sponsor:
Baylor Research Institute
Collaborating Sponsors:
DeRoyal Industries, Inc.
Conditions:
Central Line Bloodstream Infections
Eligibility:
All Genders
1-3 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.
Detailed Description
With rapid technological advancement, the increased use of vascular catheters has not only improved patient care strategies, but also contributed to the risk of infection. Unfortunately, catheter rela...
Eligibility Criteria
Inclusion
- Infants with birth weights between 500 and 1500 grams admitted to the NICU with any of the following lines will be eligible for inclusion in this study
- umbilical arterial line (UAL)
- umbilical venous line (UVL)
- peripheral arterial line (PAL)
- peripheral long line (PLL)
- central venous line (CVL)
- Each eligible subject will be randomized to receive either standard of care or silver alginate dressing. Dressings will be changed every 7 days in accordance to current facility protocols.
Exclusion
- 1\. Any infant born with a lethal abnormality or who has received topical Silver therapy will be excluded from the study.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00964093
Start Date
March 1 2009
End Date
December 1 2015
Last Update
March 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor University Medical Center - Women and Children's Services
Dallas, Texas, United States, 75204